Genomes and Genes
Summary: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Publications328 found, 100 shown here
- Cancer/testis antigens, gametogenesis and cancerAndrew J G Simpson
Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
Nat Rev Cancer 5:615-25. 2005....
- A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanomaP van der Bruggen
Ludwig Institute for Cancer Research, Brussels, Belgium
Science 254:1643-7. 1991..Thus, precisely targeted immunotherapy directed against antigen MZ2-E could be provided to individuals identified by HLA typing and analysis of the RNA of a small tumor sample...
- Frequent EpCam protein expression in human carcinomasPhilip Th Went
Institute for Pathology, University of Basel, Basel, Switzerland
Hum Pathol 35:122-8. 2004..Most soft-tissue tumors and all lymphomas were EpCam negative. It is concluded that anti-EpCam therapies, if proven to be successful, will have broad applications in a wide variety of carcinomas...
- The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosisJ S Munger
Department of Medicine, and Kaplan Cancer Center, New York University School of Medicine, New York 10016 6402, USA
Cell 96:319-28. 1999..These data identify a novel mechanism for locally regulating TGF beta 1 function in vivo by regulating expression of the alpha v beta 6 integrin...
- Cancer regression in patients after transfer of genetically engineered lymphocytesRichard A Morgan
Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
Science 314:126-9. 2006..This study suggests the therapeutic potential of genetically engineered cells for the biologic therapy of cancer...
- Nova regulates brain-specific splicing to shape the synapseJernej Ule
Howard Hughes Medical Institute and Laboratory of Molecular Neuro Oncology, The Rockefeller University, New York, New York, USA
Nat Genet 37:844-52. 2005..Validating a large set of Nova RNA targets has led us to identify a multi-tiered network in which Nova regulates the exon content of RNAs encoding proteins that interact in the synapse...
- Natural selection of tumor variants in the generation of "tumor escape" phenotypesHung T Khong
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Nat Immunol 3:999-1005. 2002..Tumor escape variants are likely to emerge after treatment with increasingly effective immunotherapies...
- Regulation of tumor pH and the role of carbonic anhydrase 9Pawel Swietach
Department of Physiology, Anatomy and Genetics, Burdon Sanderson Cardiac Science Centre, Oxford OX1 3PT, UK
Cancer Metastasis Rev 26:299-310. 2007..We also review recent evidence that may suggest a role for CA9 in coordinating pH(i) among cells of large, unvascularized cell-clusters...
- Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancersP Went
Institute of Pathology, University Hospital Basel, Schonbeinstrasse 40, 4003 Basel, Switzerland
Br J Cancer 94:128-35. 2006....
- A survey of the humoral immune response of cancer patients to a panel of human tumor antigensE Stockert
Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York 10021, USA
J Exp Med 187:1349-54. 1998..As the proportion of melanomas expressing NY-ESO-1 is 20-40% and only patients with NY-ESO-1(+) tumors have antibody, this would suggest that a high percentage of patients with NY-ESO-1(+) tumors develop an antibody response to NY-ESO-1...
- Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalphaMeelad M Dawlaty
Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Cell 133:103-15. 2008..Furthermore, mice with low amounts of RanBP2 are highly sensitive to tumor formation. Together, these data identify RanBP2 as a chromosomal instability gene that regulates Topo IIalpha by sumoylation and suppresses tumorigenesis...
- Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytesMark E Dudley
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20902, USA
Science 298:850-4. 2002..This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases...
- Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaGiao Q Phan
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 100:8372-7. 2003..This study establishes CTLA-4 as an important molecule regulating tolerance to "self" antigens in humans and suggests a role for CTLA-4 blockade in breaking tolerance to human cancer antigens for cancer immunotherapy...
- Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapyMatthew H T Bui
Department of Urology, University of California, Los Angeles, California 90095 1738, USA
Clin Cancer Res 9:802-11. 2003..To date, there are no molecular markers which can reliably predict RCC outcome. We investigated whether a novel kidney cancer marker, carbonic anhydrase IX (CAIX), is associated with progression and survival...
- MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell linesBing Yang
Department of Dermatology and Paul P Carbone Comprehensive Cancer Center, University of Wisconsin Medical School, Madison, Wisconsin 53706, USA
Cancer Res 67:9954-62. 2007..Because the expression of class I MAGE proteins is limited in normal tissues, inhibition of MAGE antigen expression or function represents a novel and specific treatment for melanoma and diverse malignancies...
- Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancerAli O Gure
Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 11:8055-62. 2005..We asked whether cancer-testis gene expression occurred coordinately, and whether it correlated with variables of disease and clinical outcome of non-small cell lung cancer (NSCLC)...
- Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancerGilbert Spizzo
Division of Hematology and Oncology, Innsbruck Medical University, Austria
Gynecol Oncol 103:483-8. 2006..To identify a potential molecular target and prognostic/predictive factor for EOC, we investigated in a retrospective study the prognostic value of Ep-CAM overexpression in EOC...
- Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes Mmp12-dependent emphysemaDavid G Morris
Lung Biology Center, Department of Medicine, San Francisco General Hospital, San Francisco, California 94143, USA
Nature 422:169-73. 2003..Furthermore, we show that a functional alteration in the TGF-beta activation pathway affects susceptibility to this disease...
- Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancerI Songun
Department of Surgery, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
Br J Cancer 92:1767-72. 2005..Loss of Ep-CAM-expression identifies aggressive tumours especially in patients with stage I and II disease. This information may be helpful in selecting patients suitable for surgery or for additional treatment pre- or postoperatively...
- Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen speciesSergei Kusmartsev
H Lee Moffitt Cancer Center, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
J Immunol 172:989-99. 2004..This study demonstrates a new mechanism of Ag-specific T cell inhibition mediated by ROS produced by ImCs in cancer...
- Cancer/testis antigens: an expanding family of targets for cancer immunotherapyMatthew J Scanlan
Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, Department of Pathology, New York, NY 10021, USA
Immunol Rev 188:22-32. 2002..Since CT antigens are immunogenic and highly restricted to tumors, their discovery has led directly to the development of antigen-specific cancer vaccines, and clinical trials with MAGE-A and NY-ESO-1 are in progress...
- High Ep-CAM expression is associated with poor prognosis in node-positive breast cancerGilbert Spizzo
Division of Haematology and Oncology, University of Innsbruck, Innsbruck, Austria
Breast Cancer Res Treat 86:207-13. 2004....
- MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agentsMartin Monte
Laboratorio Nazionale del Consorzio Interuniversitario per le Biotecnologie, Area Science Park, Padriciano 99, 34012 Trieste, Italy
Proc Natl Acad Sci U S A 103:11160-5. 2006..In addition, combined trichostatin A/ET treatment in melanoma cells expressing high MAGE-A levels reestablishes p53 response and reverts the chemoresistance...
- CLIP identifies Nova-regulated RNA networks in the brainJernej Ule
Howard Hughes Medical Institute, Rockefeller University, New York, NY 10021, USA
Science 302:1212-5. 2003..Thus, CLIP reveals that Nova coordinately regulates a biologically coherent set of RNAs encoding multiple components of the inhibitory synapse, an observation that may relate to the cause of abnormal motor inhibition in POMA...
- Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissuesA A Jungbluth
Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Int J Cancer 92:856-60. 2001..There is great variability in NY-ESO-1 expression in individual tumors, ranging from an infrequent homogeneous pattern of staining to highly heterogeneous antigen expression...
- Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survivalMeri Varga
Division of Hematology and Oncology, University of Innsbruck, Innsbruck, Austria
Clin Cancer Res 10:3131-6. 2004..This retrospective study was designed to investigate the prognostic significance of epithelial cell adhesion molecule (Ep-CAM) overexpression in human gallbladder carcinoma...
- Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cellsJens Dannull
Genitourinary Cancer Immunotherapy Program, Duke University Medical Center, Durham, North Carolina 27710, USA
J Clin Invest 115:3623-33. 2005..Our findings may have implications in the design of immune-based strategies that may incorporate the Treg depletion strategy to achieve potent antitumor immunity with therapeutic impact...
- An RNA map predicting Nova-dependent splicing regulationJernej Ule
Howard Hughes Medical Institute, New York, New York 10021, USA
Nature 444:580-6. 2006....
- Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional toleranceAlfred Zippelius
Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research and Multidisciplinary Oncology Center, University Hospital Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Cancer Res 64:2865-73. 2004..We show that both the lymph node and the tumor environments blunt T-cell effector functions and offer a rationale for the failure of tumor-specific responses to effectively counter tumor progression...
- Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumorsChandra G Rao
Immunicon Corporation, Huntingdon Valley, PA 19006, USA
Int J Oncol 27:49-57. 2005..This supports the hypothesis that this adhesion molecule is down-regulated on carcinoma cells in the circulation...
- A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancerAndrew M Scott
Ludwig Institute for Cancer Research, Melbourne Tumour Biology, Austin, and Repatriation Medical Centre, 3084 Australia
Clin Cancer Res 9:1639-47. 2003....
- Nuclear signalling by tumour-associated antigen EpCAMDorothea Maetzel
Clinical Cooperation Group Molecular Oncology, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, and Head and Neck Research Dept, Ludwig Maximilians University of Munich, Germany
Nat Cell Biol 11:162-71. 2009..In patients, EpICD was found in nuclei of colon carcinoma but not of normal tissue. Nuclear signalling of EpCAM explains how EpCAM functions in cell proliferation...
- Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significanceNaofumi Yoshida
Division of Immunoregulation, Institute for Genetic Medicine, Hokkaido University, Sapporo 060 0815, Japan
Int J Oncol 28:1089-98. 2006..MAGE-A4 expression in advanced group and T cell infiltration may provide prognostic information. Lastly, these CT antigens, especially MAGE-A4, may represent potential targets for cancer immunotherapy in patients with NSCLC...
- Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pHEliska Svastova
Centre of Molecular Medicine, Institute of Virology, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic
FEBS Lett 577:439-45. 2004..Our findings suggest that hypoxia regulates both expression and activity of CA IX in order to enhance the extracellular acidification, which may have important implications for tumor progression...
- Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancerJohannes H A M Kaanders
Department of Radiation Oncology, University Medical Center Nijmegen, 6500 HB Nijmegen, The Netherlands
Cancer Res 62:7066-74. 2002..Pimonidazole and CA9 demonstrate concordant staining patterns, but the latter is a less specific marker for hypoxia...
- NY-ESO-1 expression and immunogenicity in malignant and benign breast tumorsYurika Sugita
Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, 2 2 Yamadaoka, Suita City, Osaka 565 0871, Japan
Cancer Res 64:2199-204. 2004....
- Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapyHelen Y Wang
The Center for Cell and Gene Therapy and Department of Immunology, Baylor College of Medicine, Houston, TX 77030, USA
Immunity 20:107-18. 2004..These findings suggest that the presence of tumor-specific CD4(+) Treg cells at tumor sites may have a profound effect on the inhibition of T cell responses against cancer...
- Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pHJohanna Chiche
Institute of Developmental Biology and Cancer Research University of Nice, Centre National de la Recherche Scientifique UMR 6543, Centre A Lacassagne, 33 Avenue Valombrose, Nice, France
Cancer Res 69:358-68. 2009..Thus, hypoxia-induced CAIX and CAXII are major tumor prosurvival pH(i)-regulating enzymes, and their combined targeting shows that they hold potential as anticancer targets...
- Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-cateninEliska Svastova
Centre of Molecular Medicine, Institute of Virology, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic
Exp Cell Res 290:332-45. 2003..We conclude that CA IX has a capacity to modulate E-cadherin-mediated cell adhesion via interaction with beta-catenin, which could be of potential significance in hypoxia-induced tumor progression...
- Malignant effusions and immunogenic tumour-derived exosomesFabrice Andre
Departments of Clinical Biology, Immunology Unit, Institut Gustave Roussy, Villejuif, France
Lancet 360:295-305. 2002..To assess the role of these exosomes in vivo, we examined malignant effusions for their presence. We also investigated whether these exosomes could induce production of tumour-specific T cells when pulsed with dendritic cells...
- MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanomaJinyan Du
Department of Pediatric Hematology Oncology, Dana Farber Cancer Institute and Children s Hospital, Harvard Medical School, Boston, USA
Am J Pathol 163:333-43. 2003..Collectively, this study links three important melanoma antigens into a common transcriptional pathway regulated by MITF...
- The imprinted gene Magel2 regulates normal circadian outputSerguei V Kozlov
Cancer and Developmental Biology Laboratory, National Cancer Institute, Frederick, Maryland 21702, USA
Nat Genet 39:1266-72. 2007....
- Radioimmunoguided surgery (RIGS), PET/CT image-guided surgery, and fluorescence image-guided surgery: past, present, and futureDuxin Sun
Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
J Surg Oncol 96:297-308. 2007..PET/CT image-guided surgery only detects later stage disease. Fluorescence image-guided surgery using anti-TAG-72 antibodies may provide opportunities for intraoperative cancer detection of both gross and occult tumors...
- Symbiotic bacteria direct expression of an intestinal bactericidal lectinHeather L Cash
Center for Immunology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
Science 313:1126-30. 2006..We propose that these proteins represent an evolutionarily primitive form of lectin-mediated innate immunity, and that they reveal intestinal strategies for maintaining symbiotic host-microbial relationships...
- Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancerA Giatromanolaki
Tumour and Angiogenesis Research Group, Department of Radiotherapy Oncology, Democritus University of Thrace, Alexandroupolis 68100, Greece
Cancer Res 61:7992-8. 2001..The expression of CA9 is linked to the expression of a constellation of proteins involved in angiogenesis, apoptosis inhibition, and cell-cell adhesion disruption, which explains the strong association of CA9 with poor outcome...
- Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segmentJ Pastorek
Institute of Virology, Slovak Academy of Sciences, Bratislava
Oncogene 9:2877-88. 1994..In addition, the analysis of biological consequences of MN expression of NIH3T3 cells provides the evidence in favour of MN protein involvement in control of cell proliferation and transformation...
- Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survivalEdwin P Hui
Departments of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
Clin Cancer Res 8:2595-604. 2002....
- RAGE signaling in inflammation and arterial agingLi Lin
Laboratory of Cardiovascular Sciences, National Institute on Aging, Baltimore, Maryland, 21224, USA
Front Biosci (Landmark Ed) 14:1403-13. 2009..This review attempts to provide a comprehensive summary on both recent findings and missing pieces of the RAGE puzzle...
- The role of tumor stroma in the interaction between tumor and immune systemThomas Blankenstein
Max Delbruck Center for Molecular Medicine, Robert Rossle Strasse 10, 13092 Berlin, Germany
Curr Opin Immunol 17:180-6. 2005..These cytokines inhibit tumor-induced angiogenesis, probably through different cellular targets...
- Nova regulates GABA(A) receptor gamma2 alternative splicing via a distal downstream UCAU-rich intronic splicing enhancerB Kate Dredge
Laboratory of Molecular Neuro Oncology, Howard Hughes Medical Institute, The Rockefeller University, New York, New York 10021, USA
Mol Cell Biol 23:4687-700. 2003....
- CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patientsJ L Pujol
Montpellier Academic Hospital, Hopital Arnaud de Villeneuve, avenue du Doyen Giraud, 34295 Montpellier Cedex 5, France
Br J Cancer 90:2097-105. 2004..In conclusion CYFRA 21-1 might be regarded as a putative co-variable in analysing NSCLC outcome inasmuch as a high serum level is a significant determinant of poor prognosis whatever the planned treatment...
- Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemiaConcetta Quintarelli
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
Blood 112:1876-85. 2008..PRAME CTLs were generated almost exclusively from the naive T-cell compartment, and clonal analysis showed these cells could have high alphabetaTCR-peptide avidity. PRAME CTLs or vaccines may thus be of value for patients with CML...
- Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptorH Ikeda
Cellular Genetics Unit, Universite Catholique de Louvain, Brussels, Belgium
Immunity 6:199-208. 1997....
- Can urinary exosomes act as treatment response markers in prostate cancer?Paul J Mitchell
Section of Oncology and Palliative Medicine, School of Medicine, Cardiff University, Velindre Cancer Centre, Whitchurch, Cardiff, UK
J Transl Med 7:4. 2009..Their utility as a source of markers in urological cancer remains unstudied. Our aim in this study was to investigate the feasibility and value of analysing urinary exosomes in prostate cancer patients undergoing standard therapy...
- Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cellsCharles De Smet
Ludwig Institute for Cancer Research, Brussels Branch, 74 avenue Hippocrate, B1200 Brussels, Belgium
Mol Cell Biol 24:4781-90. 2004..We conclude that the site-specific hypomethylation of MAGE-A1 in tumor cells relies on a transient process of demethylation followed by a persistent local inhibition of remethylation due to the presence of transcription factors...
- Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunityAnna K Palucka
Baylor Institute for Immunology Research, Sammons Cancer Center, 3434 Live Oak, Dallas, TX 75204, USA
J Immunother 29:545-57. 2006..Thus, the present results justify the design of larger follow-up studies to assess the clinical response to DC vaccines loaded with killed allogeneic tumor cells in patients with metastatic melanoma...
- DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IXMilota Kaluzova
Department of Microbiology and Molecular Genetics, University of California at Irvine, College of Medicine, Irvine 92717, USA
Mol Cell Biol 24:5757-66. 2004..A model outlining the quantitative relationship between p53, HIF-1alpha, and CAIX is presented...
- Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significancePeter Jantscheff
Kantonsspital Basel, Department of Research, Basel, Switzerland
J Clin Oncol 21:3638-46. 2003..The aim of our study was to evaluate the prognostic relevance of CEACAM6, CEACAM1, and CEA tissue expression in patients with CRC...
- Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanomaE Jager
Medizinische Klinik II, Hämatologie Onkologie, Krankenhaus Nordwest, 60488 Frankfurt, Germany
J Exp Med 191:625-30. 2000..Further, the therapeutic efficacy of active immunization using antigenic HLA class I-restricted peptides may be improved by adding HLA class II-presented epitopes...
- Tumor associated antigen recognition by autologous serum in patients with breast cancerFeng Qian
Department of Biology, Indiana University, Bloomington, IN 47405, USA
Int J Mol Med 15:137-44. 2005..These clones did not react with sera from a panel of 25 healthy adult individuals. Our results demonstrate the utility of the SEREX approach for the identification of potential tumor associated antigens in human breast cancer...
- Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejectionY Kawakami
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Proc Natl Acad Sci U S A 91:6458-62. 1994....
- Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinomaMatthew H T Bui
Departments of Urology, University of California Los Angeles, California 90095 1738, USA
J Urol 171:2461-6. 2004..The natural history of renal cell carcinoma (RCC) is complex and not entirely explained by conventional prognostic factors. In this study we evaluated the prognostic value of carbonic anhydrase IX (CAIX) and Ki67 to predict survival in RCC...
- Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasionNaomi Robertson
Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
Cancer Res 64:6160-5. 2004..Thus, CAIX plays an important role in the growth and survival of tumor cells under normoxia and hypoxia, making it a potential target for cancer therapy, but is not involved in invasion...
- Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: a kinetic analysisC Schick
Department of Pediatrics, The Harvard Medical School, Children s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA
Biochemistry 37:5258-66. 1998....
- Expression of RCAS1 in human gastric carcinoma: a potential mechanism of immune escapeYuichi Nakamura
First Department of Medicine, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita ku, Sapporo 060 8638, Japan
Cancer Sci 95:260-5. 2004..The expression and distribution of RCAS1 may be involved in malignant transformation, tumor progression, histological type and tumor escape from host immune surveillance in gastric cancer...
- Squamous cell carcinoma antigen in human liver carcinogenesisM Guido
Department of Diagnostic Medical Sciences and Special Therapies, Universitè degli Studi di Padova, Italy
J Clin Pathol 61:445-7. 2008..Squamous cell carcinoma antigen (SCCA) is a serine protease inhibitor that can be overexpressed in hepatocellular carcinoma (HCC) at both molecular and protein level, but no data are available on its expression in pre-malignant stages...
- Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouseReshma Singh
Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
J Immunol 175:3663-73. 2005..monocytogenes-based HER-2/neu vaccines in a murine model of breast cancer and also that the immunogenicity of self-Ags can be increased by fusion to LLO and delivery by L. monocytogenes revealing subdominant epitopes...
- Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancerNobuaki Suzuki
Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
Int J Cancer 98:45-50. 2002..Positive peptide profiles varied among patients. These results may provide a scientific basis for a new kind of cancer immunotherapy, namely, a CTL precursor-oriented peptide vaccine, for pancreatic cancer patients...
- RNA helicase A interacts with dsDNA and topoisomerase IIalphaKai Zhou
Department of Biochemistry and Molecular Biology, Graduate School of Biomedical Sciences, University of Medicine and Dentistry of New Jersey, 185 South Orange Avenue, Newark, NJ 07013, USA
Nucleic Acids Res 31:2253-60. 2003..The putative role of RHA-topoisomerase IIalpha complex in RNA polymerase II-mediated transcription is discussed...
- Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arraysMadhumita Chatterjee
Program in Molecular Biology and Human Genetics, Barbara Ann Karmanos Cancer Institute, Wayne State University, 110 East Warren, Detroit, MI 48201, USA
Cancer Res 66:1181-90. 2006..Further work with larger panels of antigens should provide a comprehensive set of markers with sufficient sensitivity and specificity suitable for clinical testing in high-risk populations...
- The epithelial cell adhesion molecule EpCAM is required for epithelial morphogenesis and integrity during zebrafish epiboly and skin developmentKrasimir Slanchev
Georges Koehler Laboratory, Max Planck Institute of Immunobiology, Freiburg, Germany
PLoS Genet 5:e1000563. 2009..In addition, EpCAM is required for the interaction of the epithelia with underlying cell layers...
- Direct integrin alphavbeta6-ERK binding: implications for tumour growthNuzhat Ahmed
Gynaecological Cancer Research Centre, The Royal Women s Hospital, Melbourne and University of Melbourne, Melbourne, Australia
Oncogene 21:1370-80. 2002..The physical interaction between integrin alphavbeta6 and ERK2 defines a novel paradigm of integrin-mediated signalling and provides a therapeutic target for cancer treatment...
- Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific toleranceGang Zhou
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD 21231, USA
J Immunol 178:2155-62. 2007..Instead, induction of Ag-specific regulatory cells from naive cells is intrinsically influenced by the tumor microenvironment and the presence of tumor Ag...
- Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy targetChristian Potter
Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital Oxford, UK
Cell Cycle 3:164-7. 2004..As it is commonly expressed in tumours with the worst prognosis it is a potential target for therapy...
- Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancerNiels Reinmuth
Department of Medicine, Westfalische Wilhelms Universitat, 48129, Munster, Germany
Lung Cancer 36:265-70. 2002....
- Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosisAshraf J Abusamra
London Health Science Centers, London, Ontario, Canada
Blood Cells Mol Dis 35:169-73. 2005..Addition of anti-FasL antibody blocked the apoptosis induction by tumor exosomes. This study suggests that induction of T-cell apoptosis by tumor-derived exosomes appears to be a novel mechanism of tumor immune evasion...
- Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCRSachiko Okamoto
Center for Cell and Gene Therapy, Takara Bio, Inc, Shiga, Japan
Cancer Res 69:9003-11. 2009..In consequence, the vector-transduced lymphocytes showed enhanced cytotoxic activity against antigen-expressing tumor cells. Therefore, our novel TCR gene therapy may open a new gate for effective immunotherapy in cancer patients...
- Immunomic analysis of human sarcomaSang Yull Lee
Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Proc Natl Acad Sci U S A 100:2651-6. 2003..NY-SAR-35 is therefore a potential target for cancer vaccines and monoclonal antibody-based immunotherapies...
- Immunosuppressive networks in the tumour environment and their therapeutic relevanceWeiping Zou
Tulane University Health Sciences Center, Section of Hematology and Medical Oncology, 1430 Tulane Avenue, New Orleans, Louisiana 70112 2699, USA
Nat Rev Cancer 5:263-74. 2005..Why then has tumour immunotherapy resulted in a generally poor clinical efficiency? The reason might lie in the increasingly documented fact that tumours develop diverse strategies that escape tumour-specific immunity...
- Expression of extracellular matrix metalloproteinase inducer and enhancement of the production of matrix metalloproteinases in rheumatoid arthritisTetsuya Tomita
Osaka University Graduate School of Medicine, 2 2 Yamada oka, Suita, Osaka 565 0871, Japan
Arthritis Rheum 46:373-8. 2002..To investigate the expression of extracellular matrix metalloproteinase inducer (EMMPRIN) at sites of joint destruction in rheumatoid arthritis (RA) and to correlate it with the production of matrix metalloproteinases (MMPs)...
- Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancerFabrice Barlesi
Faculty of Medicine, Universite de la Mediterranee, Assistance Publique Hopitaux de Marseille, Service d Oncologie Thoracique, Marseille, Cedex 09, France
Respir Med 98:357-62. 2004..To assess the value of Cyfra 21-1, carcino-embryonic antigen (CEA) and neuron-specific enolase (NSE) combined, all three together as prognostic factors in advanced stage non-small cell lung cancer (NSCLC) patients...
- Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transitionChi Ming Li
Institute for Cancer Genetics, Columbia University, New York, New York, USA
Am J Pathol 160:2181-90. 2002..The WT-signature set also contained the Wnt receptor FZD7, the tumor antigen PRAME, the imprinted gene NNAT and the metastasis-associated transcription factor E1AF...
- CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody productionG Zeng
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 98:3964-9. 2001....
- Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanomaAndreas Mackensen
Department of Hematology Oncology, University of Regensburg, Franz Josef Strauss Allee 11, D 93042 Regensburg, Germany
J Clin Oncol 24:5060-9. 2006..A phase I study was conducted to test the feasibility, safety, and survival of adoptively transferred Melan-A-specific CTL lines in melanoma patients...
- Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agentsJian Ren
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 5:163-75. 2004..These findings indicate that MUC1 attenuates the apoptotic response to DNA damage and that this oncoprotein confers resistance to genotoxic anticancer agents...
- Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patientsChristopher J Wheeler
Maxine Dunitz Neurosurgical Institute, Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, California, USA
Cancer Res 68:5955-64. 2008..As such, our findings offer unique opportunities to identify cellular and molecular components of clinically meaningful antitumor immunity in humans...
- Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME geneShelly R Gunn
Department of Pathology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
Leuk Res 33:1276-81. 2009..Quantitative real-time PCR revealed that ZNF280A, ZNF280B, and PRAME mRNA expression was significantly lower in the 22q11 deletion cases compared to non-deleted cases...
- Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trialRichard Harrop
Oxford BioMedica UK Ltd, The Medawar Centre, Oxford Science Park, Oxford, United Kingdom
Clin Cancer Res 12:3416-24. 2006..The primary objectives were to assess the safety and immunogenicity of ascending doses of TroVax and to determine the biodistribution of the vector...
- Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9M J Scanlan
Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York 10021, USA
Cancer Lett 150:155-64. 2000..The coexpression pattern of these antigens provides a foundation for developing a polyvalent lung cancer vaccine...
- Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinomaYoshihisa Fujita
Department of General and Gastroenterological Surgery, Osaka Medical College, 2 7 Daigaku machi, Takatsuki City, Osaka 569 8686, Japan
Cancer Lett 263:280-90. 2008..We have identified an autoantibody against Hsp70 in ESCC patients. The proteomic approach implemented herein offers a powerful tool for identifying novel serum markers that may display clinical utility against cancer...
- Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenograftsD C Saffran
UroGenesys, Inc, 1701 Colorado Avenue, Santa Monica, CA 90404, USA
Proc Natl Acad Sci U S A 98:2658-63. 2001..These studies suggest PSCA as an attractive target for immunotherapy and demonstrate the therapeutic potential of anti-PSCA mAbs for the treatment of local and metastatic prostate cancer...
- A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen geneS S Schneider
Department of Pediatrics, Harvard Medical School, Children s Hospital, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 92:3147-51. 1995..Further characterization of the region should determine whether the differential expression of the SCCA genes plays a causal role in development of more aggressive squamous cell carcinomas...
- The 65 and 110 kDa SR-related proteins of the U4/U6.U5 tri-snRNP are essential for the assembly of mature spliceosomesO V Makarova
Max Planck Institute for Biophysical Chemistry, Department of Cellular Biochemistry, Am Fassberg 11, D 37077 Gottingen, Germany
EMBO J 20:2553-63. 2001..Moreover, since both proteins contain an N-terminal RS domain, they could mediate the association of the tri-snRNP with pre-spliceosomes by interaction with members of the SR protein family...
- EpCAM expression in retinoblastoma: a novel molecular target for therapySubramanian Krishnakumar
Department of Ocular Pathology, Vision Research Foundation, Sankara Nethralaya, 18 College Road, Chennai 600006, Tamil Nadu, India
Invest Ophthalmol Vis Sci 45:4247-50. 2004..It was first determined whether EpCAM is expressed in retinoblastoma and then whether EpCAM reactivity correlates with tumor aggressiveness...
- Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapyRadoslav Chekerov
Department of Obstetrics and Gynecology, Charite University Hospital, Campus Virchow, Berlin, Germany
Neoplasia 8:38-45. 2006..The aim of this study was to evaluate the expression of topoisomerase IIalpha (TOP2A) in epithelial and stromal cells of ovarian cancer...
- Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemiaChristina A Ortmann
Klinik für Hämatologie, Zentrum für Konservative Onkologie, Universitatsklinikum Essen, Hufelandstrasse 55, 45122, Essen, Germany
Ann Hematol 87:809-18. 2008..Such a role is further supported by the observation that treatment of PRAME-negative cell lines U-937 and THP-1 with the demethylating agent 5'-Aza-2'dC resulted in a dose-related upregulation of PRAME expression...
- Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomasDavid Hedley
Division of Experimental Therapeutics and Department of Radiation Oncology, Ontario Cancer Institute Princess Margaret Hospital, Toronto, Ontario, Canada
Clin Cancer Res 9:5666-74. 2003..Recent studies suggest that carbonic anhydrase IX (CA IX), which is regulated via hypoxia-inducible factor 1, is a useful intrinsic marker of tumor hypoxia...
- Antibody-drug conjugates for cancer therapyPaul J Carter
Seattle Genetics, Inc, Bothell, Washington 98021, USA
Cancer J 14:154-69. 2008..This review details these advances, discusses some of the remaining challenges, and overviews ADCs currently in clinical trials for cancer therapy...
- PRAME expression and clinical outcome of breast cancerM T Epping
Division of Molecular Carcinogenesis and Centre for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands
Br J Cancer 99:398-403. 2008..We conclude that PRAME expression is a prognostic marker for clinical outcome of breast cancer, independent of traditional clinicopathological markers...
- Bystander elimination of antigen loss variants in established tumorsMichael T Spiotto
Department of Pathology and the Committee on Immunology, The University of Chicago, Chicago, Illinois 60637, USA
Nat Med 10:294-8. 2004..These results highlight the general importance of targeting the tumor stroma to prevent the escape of variant cancer cells...
- Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasionL M Shaw
Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
Cell 91:949-60. 1997..The small G protein Rac is required downstream of PI3K for invasion. These studies define a mechanism by which the alpha6beta4 integrin promotes carcinoma invasion and invoke a novel function for PI3K signaling...
- Mice with Human Dendritic Cells to Test Vaccine PotencyA Palucka; Fiscal Year: 2004..The experiments proposed here would lay ground for further use of SCID-hu/DCs mice to study other vaccines and demonstrate development of protective immunity upon in vivo rechallenge. ..
- Dendritic Cells and Breast Cancer ImmunityA Palucka; Fiscal Year: 2004..Overall, this proposal will permit us to demonstrate that efficient breast cancer immunity can be generated and used to reject the tumor thus permitting development of novel treatment modalities in breast cancer. ..
- VACCINES WITH MHC CLASS II-RESTRICTED MELANOMA PEPTIDESCraig Slingluff; Fiscal Year: 2004....
- Molecular Dissection of T Cell AnergyThomas Gajewski; Fiscal Year: 2005..Ultimately, a complete understanding of the anergic state on the molecular level should guide the development of novel pharmacologic therapies to promote or reverse peripheral tolerance in vivo. ..
- Technologies To Block Gene Expression in Normal T CellsThomas Gajewski; Fiscal Year: 2003..abstract_text> ..
- DENDRITIC CELL IMMUNOTHERAPY FOR LUNG AND COLON CANCERLawrence Fong; Fiscal Year: 2003..The proposed studies will provide the foundation for simplified yet more potent DC targeted cancer immunotherapy for the future. ..
- Biochemical/Molecular Changes Upon Naive T Cell PrimingThomas Gajewski; Fiscal Year: 2005....
- MULTI-EPITOPE MELANOMA PEPTIDE VACCINATION WITH GM-CSFCraig Slingluff; Fiscal Year: 2004..abstract_text> ..
- MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLSCraig Slingluff; Fiscal Year: 2009....
- Vaccination with Regulatory T Cell DepletionMichael Morse; Fiscal Year: 2007..Future studies will assess whether the greater magnitude and durability of the CEA-specific immune responses will translate into a long-term clinical benefit. [unreadable] [unreadable] [unreadable]..
- Targeted Molecular Therapeutics for Melanoma: CCI-779 and BevacizumabCraig Slingluff; Fiscal Year: 2008..The following proposal is a clinical trial to evaluate the effects of bevacizumab and CCI-779, which interfere with vascularization and tumor growth, for the treatment of melanoma. [unreadable] [unreadable] [unreadable]..
- T Cell Responsiveness and Homeostasis in Anti-TumorThomas F Gajewski; Fiscal Year: 2010..T cell transduction and tumor transfectants will be examined using factors identified to be useful from the TCR Tg model and mechanisms of improved tumor control will be dissected. ..
- DEXASOME BASED IMMUNOTHERAPY OF LUNG CANCERMichael Morse; Fiscal Year: 2002..This clinical trial will form the background for further trials designed to demonstrate both immunology and clinical benefits of dexosome-based immunotherapy. ..
- Multi-Peptide/IL 12 Melanoma VaccineThomas Gajewski; Fiscal Year: 2006..Understanding these mechanisms will illuminate the next level of intervention to develop to increase the clinical response to the immunotherapy of melanoma. [unreadable] [unreadable]..
- Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk MelanomaCRAIG LEE SLINGLUFF; Fiscal Year: 2010....
- DGK in T Cell Regulation and ToleranceThomas F Gajewski; Fiscal Year: 2010..Ti U,0 ._0 ... ur tow 5a' c' OUP O-0 N-0 0-0 V,12 oar aux. :E, -'1 .., (gyp afl' coo COD m='(Dm o03-' _=c 3m03 l17 CDG'O COB 111 ..
- AFP-BASED PRIME-BOOST IMMUNOTHERAPY OF HCCLISA BUTTERFIELD; Fiscal Year: 2006..These proposed studies will permit us to determine the immunological impact of a plasmid prime-adenoviral boost directed towards a self tumor antigen and to define mechanisms of antigen presentation. ..
- Polarized DC as Melanoma Vaccine: Phase 1 EvaluationPawel Kalinski; Fiscal Year: 2006....
- Green tea-mediated inhibition of aberrant DNA hypermethylation in prostate cancerADAM KARPF; Fiscal Year: 2007..unreadable] [unreadable] [unreadable] [unreadable]..
- Dendritic Cell Vaccination During Lymphoid ReconstitutionJeffrey Weber; Fiscal Year: 2008..Toxicity as well as clinical response will be secondary endpoints. The cohort with the optimal level of immune response will be taken forward in future studies. ..
- CHEMOIMMUNOTHERAPY FOR BREAST CANCER TREATMENTLeisha Emens; Fiscal Year: 2006..abstract_text> ..
- Survival of CD4+CD25+ Regulatory T CellsXiao Feng Yang; Fiscal Year: 2007....
- B7-DC Cross-linking antibody immunotherapySvetomir Markovic; Fiscal Year: 2008..If successful, this "proof-of-principle" clinical trial will justify further development of B7-DC XAb as a cancer therapeutic with potential universal application for all malignant disorders. [unreadable] [unreadable] [unreadable]..
- HPV DNA VACCINE FOR CERVICAL PRE NEOPLASIAJeffrey Weber; Fiscal Year: 2003..To insure that spontaneous regression does not account for a portion of the responses, baseline measurements will be followed one month later by a second set of assessments prior to the start of the vaccine. ..
- IN VITRO/IN VIVO ACTIVATED DENDRITIC CELLS FOR MELANOMAJeffrey Weber; Fiscal Year: 2003....
- Regulation of DC Activity by Memory and Effector CD8+ T CellsPawel Kalinski; Fiscal Year: 2010..abstract_text> ..
- Epigenetic regulation of cancer/germ-line antigen gene expressionAdam R Karpf; Fiscal Year: 2010..Furthermore, this study will provide key information relevant for understanding the outcome and improving the future design of clinical vaccine trials for the treatment of ovarian cancer. ..
- IL-12 as an Adjuvant for a Melanoma Peptide VaccineJeffrey Weber; Fiscal Year: 2003..The results of those assays will be used to design randomized phase III trials for resected high risk melanoma and to develop strategies for overcoming antigen-specific unresponsiveness in melanoma patients. ..
- Defining Molecular Markers for Tumor HypoxiaQUYNH THU XUAN LE; Fiscal Year: 2010..abstract_text> ..
- CTLA-4 Inhibition and Autoimmunity in MelanomaJeffrey Weber; Fiscal Year: 2008..abstract_text> ..
- Tumor-reactive IgG in the diagnosis of ovarian cancerDouglas Taylor; Fiscal Year: 2005..Ultimately, antigenic proteins, linked with histologic type and stage of disease, will be combined into the development of protein arrays to screen for circulating reactive IgG as an early diagnostic test. ..
- Immune Correlates of HSV-2 Disease SeverityDavid Koelle; Fiscal Year: 2007....
- EGFR activity in T cell-influenced glioma invasiveness & chemosensitivityChristopher Wheeler; Fiscal Year: 2007..unreadable] [unreadable]..
- TAG-72 Targeted Imaging for Cancer DetectionMary Rusckowski; Fiscal Year: 2007..The agent developed in these studies could be of great benefit in the diagnosis of ovarian cancer, not only the primary site of disease, but possibly metastases as well. [unreadable] [unreadable] [unreadable]..
- Autoimmune vitiligo as a roadmap to melanoma therapyISABELLE LE POOLE; Fiscal Year: 2007..Importantly, the cloning of high affinity T cell receptors in retroviral vectors may be suitable for introduction into patient PBL for treatment of malignant melanoma. ..
- Thymocyte tuning after selection: mechanisms to avoid autoreactivityTerri M Laufer; Fiscal Year: 2010..These experiments will define the mechanisms which regulate a critical thymic pathway that the immune system utilizes to avoid autoreactivity. ..
- Genetic Determinants of Bipolar DisorderPamela Sklar; Fiscal Year: 2007..An important dividend of this large study will be the expansion of the repository to include DNA data on relatives and on an independent sample of controls, thus facilitating future genetic studies. [unreadable] [unreadable]..
- Genome Integrative Pathway Modeling of Diabetic AtherosclerosisJae K Lee; Fiscal Year: 2010..Our GIPaM technology will also greatly enhance pathway discovery/modeling capability in other fields of the biomedical science. ..
- Autoantibody Signatures as Biomarkers of Interstitial Cystitis.Brian Liu; Fiscal Year: 2008..abstract_text> ..
- CREB in Differentiation of Bronchial Mucous CellsJa Seok Koo; Fiscal Year: 2007..This application will address this hypothesis by determining the molecular mechanisms whereby CREB regulates normal and aberrant bronchial epithelial cell differentiation. ..
- Pigmentation and Diversity ConferenceISABELLE LE POOLE; Fiscal Year: 2007..unreadable] [unreadable] [unreadable] [unreadable]..
- Immunotherapeutic strategies for breast cancerYVONNE J PATERSON; Fiscal Year: 2010....
- Tumor environmental CD4+CD25+ T cellsWeiping Zou; Fiscal Year: 2006..We hypothesize that MDC plus IL-2 are beneficial to tumor immunity by modifying the regulatory function ofCD4 + Tr cells. We predict that MDC plus IL-2, not MDC alone may be a strategy for treating cancer patients. ..
- Haplotype and Expression Mapping of Prepulse InhibitionPamela Sklar; Fiscal Year: 2006..unreadable] [unreadable]..
- IMMUNOLOGICAL MECHANISM OF INFLAMMATION IN UVEITIS & EAEGrazyna Adamus; Fiscal Year: 2001..3) Examine the role of cytokines and chemokines in the recruitment of cell to the eye in primary and recurrent uveitis associated with EAE after immunization of Lewis rats with MBP. ..
- Novel Immunotherapy for the treatment of cervical cancerVafa Shahabi; Fiscal Year: 2005..In addition, this technology can be applied to other cancers and infectious diseases, projects that are in preclinical development. ..
- Intradermal vaccinia:T-cell specificity and skin homingDavid Koelle; Fiscal Year: 2005..2) Measure E-selectin binding by vaccinia-specific CD8 cells, and 2.3) Compare CLA and E-selectin binding by vaccinia-specific T-cells in recent and distant vaccines. ..
- Rapid Immunoassays for Detecting Pathogenic BacteriaMichael Wilson; Fiscal Year: 2004..EIC has a commercial path for assay technology through in-house manufacturing, sale of electrochemical assays and hand-held assay readers, and out-licensing of our multianalyte immunoassay technology. ..
- INCREASE/gp120 IMMUNOGENICITY/LINKED ALPHA-GAL EPITOPESUri Galili; Fiscal Year: 2005..We will then also collaborate with a group studying immune responses in monkeys to determine the efficacy of this vaccine in a primate model. ..
- BIOCHEMISTRY OF UTERINE HEPARAN SULFATE RECEPTORSDaniel Carson; Fiscal Year: 2006..In addition, we will examine the role(s) that HIP/L29 plays in vivo using transgenic mouse models. ..
- Anti-GD3 NKT cells as effector cells against melanomaPaul Chapman; Fiscal Year: 2006..This will provide initial support for an immunotherapeutic approach based on antigen-specific NKT cells. [unreadable] [unreadable]..
- CONFOCAL MICROSCOPY SYSTEMSergei Rudchenko; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- Enhancing the immunogenicity of idiotypes for therapy of Non-Hodgkin's lymphomaYvonne Paterson; Fiscal Year: 2006..We will also have tested 3 possible adjuvants to enhance its delivery. This will set the stage for a Phase II proposal focused on preparations for entering clinical trials. [unreadable] [unreadable] [unreadable]..
- HSV Immunotherapeutic VaccineDavid Koelle; Fiscal Year: 2005....
- Ovarian Cancer: Strategies for consolidationPaul Sabbatini; Fiscal Year: 2006..Promising strategies will be moved to patients in primary remission (Specific Aim 1) with a current median time to treatment failure of 18-21 months...
- MELANOMA ANTIGENS INDENTIFIED FROM GMCSF VACCINATIONFRANK HODI; Fiscal Year: 2002..Further identification of immunogenic antigens in melanoma offers promise for future therapies. ..
- A New Biomarker for Ovarian Cancer DetectionEleftherios Diamandis; Fiscal Year: 2003..In this grant proposal, we describe further studies, which will examine in greater detail, the ability of a test for the amount of this protein in blood to correctly diagnose the presence of ovarian cancer. ..
- Monoclonal Antibody Therapy Induction of Adaptive ImmunityLouis Weiner; Fiscal Year: 2008..A candidate antibody for clinical development will emerge, as will generally useful information regarding the structural features of antibodies that contribute to ADCC and in vivo efficacy. [unreadable] [unreadable] [unreadable]..
- Human Kallikrein 4 (hK4): A New Prostatic Biomarker?Eleftherios Diamandis; Fiscal Year: 2003..If successful, our research will contribute to the development of new prostatic biomarkers and possibly, to better diagnosis which may lead to better clinical outcomes and reduced healthcare costs. ..
- KALLIKREINS AS DIAGNOSTIC MARKERS OF OVARIAN CARCINOMAEleftherios Diamandis; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- Targeting myeloma via dendritic cellsMadhav Dhodapkar; Fiscal Year: 2009..abstract_text> ..
- IMMUNOGENICITY OF HIV PROTEINS DELIVERED BY LIVE VECTORYvonne Paterson; Fiscal Year: 2004..These studies will start in year 2 of the proposal. The hypothesis of this aim is that the attenuated strains will as effective as wild-type Listeria in delivering SHIV antigens to the immune system. ..
- Bacterial vector vaccine: Her-2/neu expressing tumorsYvonne Paterson; Fiscal Year: 2005..This work will demonstrate the utility of the L. monocytogenes-based vaccines, thus setting the stage for further development of a breast cancer therapeutic that can be used in humans. ..
- Adaptive Immunity from High Affinity Anti-HER2/neu Monoclonal AntibodiesLouis M Weiner; Fiscal Year: 2010..A candidate antibody for clinical development will emerge, as will generally useful information regarding the structural features of antibodies that contribute to ADCC and in vivo efficacy. ..
- CSF DEFICIENCY AND ANTITUMOR IMMUNITYGlenn Dranoff; Fiscal Year: 2004..3). To develop strategies for reconstituting tumor defense in mice deficient in GM-CSF, IL-3, and IFN-gamma. ..
- DC-CD4 interactions in Th2 differentiationTerri Laufer; Fiscal Year: 2006..abstract_text> ..
- ERAB, A BETA, NEUROTOXICITY AND ALZHEIMERS DISEASEShi Du Yan; Fiscal Year: 2003..abstract_text> ..
- Phase 1b Active Immunotherapy with HER-2 Multi-epitope vPravin Kaumaya; Fiscal Year: 2003..abstract_text> ..
- AFP-Based Immunotherapy for Hepatocellular CarcinomaAntoni Ribas; Fiscal Year: 2006..In summary, I propose a clinically-oriented research program that translates this original work into novel, evidence-based immnunotherapy trials for hepatocellular carcinoma. ..
- STRUCTURE/CONFORMATION ASPECTS IN PEPTIDE VACCINESPravin Kaumaya; Fiscal Year: 2001....
- Targets of Immune-Mediated Tumor DestructionGlenn Dranoff; Fiscal Year: 2009..Determine whether vaccination with the murine homologs of these antigens can stimulate protective immunity against challenge with murine melanoma cells. ..
- T cell diversity in the induction of autoimmunityTerri Laufer; Fiscal Year: 2006..Understanding the requirements for T cell diversity and the interactions between "graft" T cells and host antigen presenting cells offers improved immunologic targets for preventing GVHD following bone marrow transplant. ..
- Progenitor Cell Dysfunction and Impaired Vasculogenesis*Michael Brownlee; Fiscal Year: 2008..rational development of novel strategies to restore normal compensatory vasculogenesis in diabetes, thus preventing the poor outcome of cardiovascular events (Ml, stroke, amputation) associated with the disease [unreadable] [unreadable]..
- ENHANCING TUMOR VACCINES WITH CO-STIMULATORY MOLECULESHoward Kaufman; Fiscal Year: 2004..This may have important implications for the future design of tumor vaccines in melanoma and other settings. ..
- INTRACELLULAR GLYCATION AND DIABETIC COMPLICATIONSMichael Brownlee; Fiscal Year: 2007..Supershift experiments will use commercially availableantibodies. IP-westernsof cell extracts will be immunoblotted with antibodies to glyoxalase I-substrate-derived advanced glycationendproducts. ..
- INTRACELLULAR GLYCATION AND DIABETIC COMPLICATIONSMichael Brownlee; Fiscal Year: 2006..Supershift experiments will use commercially available antibodies. IP-westerns of cell extracts will be immunoblotted with antibodies to glyoxalase I-substrate- derived advanced glycation endproducts. ..
- The Role of RAGE and EAEShi Du Yan; Fiscal Year: 2005....
- CHIMERIC AND MULTIVALENT HER 2 CANCER VACCINE STRATEGIESPravin Kaumaya; Fiscal Year: 2003..This construct is now being tested in an NCI funded Phase 1b Clinical Trial at the Ohio State University. The result of this study may provide insight for the development of peptide vaccines against other tumor-associated antigens. ..
- Peptide Therapeutic Approaches for Immune TolerancePravin Kaumaya; Fiscal Year: 2003..abstract_text> ..
- BD Biosciences FACS Canto Flow CytometerLAWRENCE LAMB; Fiscal Year: 2006..The laboratory will require an instrument that will serve the laboratory in the development and execution of advanced cell therapy trials. [unreadable] [unreadable]..
- Hu1D10 in CLL: CLINICAL AND LABORATORY STUDIESJohn Byrd; Fiscal Year: 2006..abstract_text> ..